This molecular diagnostic test detects mutations in the EGFR (Epidermal Growth Factor Receptor) gene using tumor tissue samples. EGFR mutations are frequently observed in non-small cell lung cancer (NSCLC) and are critical for selecting effective EGFR-targeted therapies. The test covers exons 18, 19, 20, and 21, including key driver mutations and the T790M resistance mutation.
Genes Covered: EGFR (Exon 18,19,20,21) including T790M
Who Is This Test For?
Patients diagnosed with non-small cell lung cancer, where EGFR mutation status will influence first- or second-line treatment decisions.
Key Features
Comprehensive analysis of EGFR exons 18–21
Detects common activating mutations such as L858R and exon 19 deletions (Del19)
Includes detection of the T790M resistance mutation
Tissue-based testing ensures high analytical sensitivity
Clinical Applications
Identifies patients who may benefit from EGFR-targeted therapies (e.g., gefitinib, erlotinib, osimertinib)
Detects resistance mutations (such as T790M) to inform second-line therapy choices
Enables personalized treatment planning for improved clinical outcomes
